Home
Search
Search Results
Previously Searched
3145 results found
Expand All
Apply All
3145 results found

Good Day BIO: USTR punts decision on IP waiver
Good Day BIO Newsletter  •  December 7, 2022
USTR wants to extend the deadline to decide on the expansion of the COVID IP waiver—a good sign, we hope. Plus, the COP15 biodiversity conference begins, and two important health awareness weeks come to an end. (862 words, 4 minutes, 18 seconds)
Read More

Good Day BIO: Who invents new drugs? (Spoiler: We do.)
Good Day BIO Newsletter  •  December 6, 2022
A new study provides new insight into who develops new drugs—and no surprise, small biotechs in the U.S. play a starring role. Plus, news from USTR on the IP waiver expansion and a new report highlighting the role for biotech in transforming food systems. (754 words, 3 minutes, 46 seconds)  P.S. Today, BIO’s John Murphy will join a free virtual event hosted by The Hill, Reimagining the Pharma Supply Chain—you can watch here at 1 PM ET.
Read More

BIO Letter to the EEOC on Special Carve Outs
Letters, Testimony & Comments  •  December 5, 2022
Notice of Availability and Request for Comment: Equal Employment Opportunity Commission (EEOC) Draft Strategic Plan 2022–2026
Read More
EEOC Letter

Good Day BIO: Bivalent boosters save lives – if people get them
Good Day BIO Newsletter  •  December 5, 2022
New data shows the updated COVID vaccines prevent infection and death—but people aren’t getting them. Plus, it’s National Influenza Vaccination Week—another shot you need to get ASAP—and World Soil Day. (536 words, 2 minutes, 40 seconds)
Read More

Good Day BIO: How to beat the tripledemic
Good Day BIO Newsletter  •  December 2, 2022
Everyone’s talking about the so-called “tripledemic,” but we already have the tools to beat it. And what’s better than sliced bread? How about climate-resistant wheat? We look at new developments. (715 words, 3 minutes, 34 seconds)
Read More

Good Day BIO: On World AIDS Day, equity is in the spotlight
Good Day BIO Newsletter  •  December 1, 2022
December begins with World AIDS Day—we look at how biotech has driven progress, and how equity needs to be at the center to eradicate the disease. Plus, we look at how sugarcane is sweetening the potential of biotech to address climate change. (624 words, 3 minutes, 7 seconds)
Read More

Good Day BIO: 40 million kids are at risk of measles
Good Day BIO Newsletter  •  November 30, 2022
Today, we look at the need to get childhood immunization—especially for measles—back on track, and the latest updates on the climate provisions of the Inflation Reduction Act. (581 words, 2 minutes, 54 seconds)
Read More

Coalition Letter in Support of McKalip & Taylor Nominations
Letters, Testimony & Comments  •  November 29, 2022
A coalition of groups, including BIO and several of its member companies, wrote Senate leaders urging confirmation of Doug McKalip as Chief Agricultural Negotiator for USTR and Alexis Taylor as Under Secretary for Trade and Foreign Agricultural Affairs at USDA.
Read More

Good Day BIO: U.S. warns Mexico of legal action on corn ban
Good Day BIO Newsletter  •  November 29, 2022
Agriculture Secretary Tom Vilsack met with Mexican President Andres Manuel Lopez Obrador on the biotech corn ban—here’s what happened. The new episode of the I am BIO Podcast looks at the untapped market for women’s health products. P.S. It’s Giving Tuesday—if you’re planning to give, we encourage you to keep patient advocacy organizations in mind! (672 words, 3 minutes, 21 seconds)
Read More

Let’s Get Uncomfortable: Talking About Women’s Health
I am BIO Podcast  •  November 29, 2022
Talking about women’s health has been a taboo subject for some time, contributing to a lack of innovation in the sector. Still today, many are uncomfortable discussing the topic. Consequently, only 2% of medical products in the pipeline are for women’s health and only 2% of all venture capital dollars go into developing these products. In this episode, we talk with two women in biotech who are trying to change that narrative and infuse more investment in innovations that meet the needs of half the population.
Read More
podcast